The FDA granted accelerated approval to Ascendis Pharma’s once‑weekly TransCon CNP (now Yuviwel; navepegritide) for children aged two and older with achondroplasia, the most common form of dwarfism. The decision was based on demonstrated increases in annualized growth velocity (AGV) in pivotal studies; confirmatory trials are required as a post‑marketing condition. Yuviwel’s approval introduces weekly dosing competition to BioMarin’s daily Vosoritide (Voxzogo) and may shift prescribing dynamics for pediatric growth therapy. Ascendis expects to make the drug available to prescribers in the second quarter and has not yet released pricing details. Regulators granted the approval under accelerated pathways that accept surrogate markers — here, AGV — with the stipulation that Ascendis confirm durability and long‑term outcomes in ongoing or new clinical studies.